期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 61, 期 1, 页码 134-146出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2012.07.021
关键词
Kidney disease progression; uric acid
资金
- ISN Fellowship
- [1K23DK088833]
- [1R01 DK081473-01A1]
- [1R01DK078112-01A2]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078112, K23DK088833, R01DK081473] Funding Source: NIH RePORTER
The prevalence of chronic kidney disease (CKD) has increased and will continue to increase in the United States and worldwide. This is alarming considering that CKD is an irreversible condition and patients who progress to chronic kidney failure have reduced quality of life and high mortality rates. As such, it is imperative to identify modifiable risk factors to develop strategies to slow CKD progression. One such factor is hyperuricemia. Recent observational studies have associated hyperuricemia with kidney disease. In addition, hyperuricemia is largely prevalent in patients with CKD. Data from experimental studies have shown several potential mechanisms by which hyperuricemia may contribute to the development and progression of CKD. In this article, we offer a critical review of the experimental evidence linking hyperuricemia to CKD, highlight gaps in our knowledge on the topic as it stands today, and review the observational and interventional studies that have examined the potential nephroprotective effect of decreasing uric acid levels in patients with CKD. Although uric acid also may be linked to cardiovascular disease and mortality in patients with CKD, this review focuses only on uric acid as a potential therapeutic target to prevent kidney disease onset and progression. Am J Kidney Dis. 61(1):134-146. (C) 2012 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据